Skip to main content
Figure 4 | Alzheimer's Research & Therapy

Figure 4

From: Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies

Figure 4

18F-THK523 and 118F-florbetaben positron emission tomography scans in a progressive supranuclear palsy patient. Representative 18F-florbetaben (18F-FBB, left) and 18F-THK523 (18F-THK, right) transaxial images at three different brain levels of a 79–year-old PSP patient with a Mini Mental State Examination score of 26. Visual inspection reveals no cortical retention of either 18F-THK523 or 18F-florbetaben, despite a postmortem immunohistological examination (see Figure 3 5 months after PET evaluation), confirming the presence of tau lesions. SUVR, Standardised uptake value ratio.

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193